171 related articles for article (PubMed ID: 32702801)
1. Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study.
Wushouer H; Luo Z; Guan X; Shi L
Int J Health Policy Manag; 2022 Feb; 11(2):218-223. PubMed ID: 32702801
[TBL] [Abstract][Full Text] [Related]
2. Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study.
Guan X; Wushouer H; Yang M; Han S; Shi L; Ross-Degnan D; Wagner AK
BMJ Open; 2019 Nov; 9(11):e031658. PubMed ID: 31784440
[TBL] [Abstract][Full Text] [Related]
3. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
Rong X; Yin J; Duan S; Sun Q; Babar ZU
BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
[TBL] [Abstract][Full Text] [Related]
4. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
[TBL] [Abstract][Full Text] [Related]
5. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
[TBL] [Abstract][Full Text] [Related]
6. Does price deregulation increase drug price in China? An interrupted time series analysis.
Xiong Y; Xu J; Gao Y
Int J Health Plann Manage; 2021 Sep; 36(5):1653-1665. PubMed ID: 34028086
[TBL] [Abstract][Full Text] [Related]
7. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
[TBL] [Abstract][Full Text] [Related]
8. Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis.
Zhang L; Wang X; Yao H; Ding B; Gao X; Li X
Int J Equity Health; 2024 Jun; 23(1):116. PubMed ID: 38840134
[TBL] [Abstract][Full Text] [Related]
9. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
Zhao B; Wu J
Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
[TBL] [Abstract][Full Text] [Related]
10. Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis.
Yi H; Shi F; Wang Z; Kuai L; Xu D; Xie Y; Xing H
BMJ Open; 2023 Oct; 13(10):e064811. PubMed ID: 37852769
[TBL] [Abstract][Full Text] [Related]
11. Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis.
Sun Y; Zhu Z; Zhang J; Han P; Qi Y; Wang X; Yang L
Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457445
[TBL] [Abstract][Full Text] [Related]
12. The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis.
Ding Y; Zheng C; Wei X; Zhang Q; Sun Q
BMC Public Health; 2022 Dec; 22(1):2363. PubMed ID: 36527037
[TBL] [Abstract][Full Text] [Related]
13. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals.
Meng Q; Cheng G; Silver L; Sun X; Rehnberg C; Tomson G
Health Policy Plan; 2005 May; 20(3):185-96. PubMed ID: 15840634
[TBL] [Abstract][Full Text] [Related]
14. Impact of China's healthcare price reforms on traditional Chinese medicine public hospitals in Beijing: an interrupted time-series study.
Zhu D; Shi X; Nicholas S; Bai Q; He P
BMJ Open; 2019 Aug; 9(8):e029646. PubMed ID: 31401602
[TBL] [Abstract][Full Text] [Related]
15. The impacts of the national centralized drug procurement policy on the use of policy-related antibiotic agents: the case of Shaanxi province, China.
Yang C; Ye D; Yan K; Xiang C; Liu S; Gu J; Liu Y; Fang Y
Expert Rev Anti Infect Ther; 2023 Jun; 21(6):675-684. PubMed ID: 37013799
[TBL] [Abstract][Full Text] [Related]
16. Impact of China's zero mark-up drug policy on drug cost of NCDs' outpatients: an interrupted time series analysis.
Du J; Xie J; Qian Y; Wu M; Huang W; Yin J; Peng X; Deng D
BMC Health Serv Res; 2021 Apr; 21(1):404. PubMed ID: 33926444
[TBL] [Abstract][Full Text] [Related]
17. Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis.
Wang J; Li P; Wen J
BMC Health Serv Res; 2020 Jun; 20(1):519. PubMed ID: 32513170
[TBL] [Abstract][Full Text] [Related]
18. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
Wang N; Yang Y; Xu L; Mao Z; Cui D
BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
[TBL] [Abstract][Full Text] [Related]
19. An empirical study of the impact of generic drug competition on drug market prices in China.
Yina C; Pengcheng L; Haomiao N; Yang C
Front Public Health; 2023; 11():1146531. PubMed ID: 37304112
[TBL] [Abstract][Full Text] [Related]
20. The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis.
Qin Z; He M; Shen H; Liu S; Xu S; Chen L
Front Public Health; 2024; 12():1381786. PubMed ID: 38903594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
